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Our success in producing an active epidermal growth factor receptor (EGFR) tyrosine kinase in Escherichia coli encouraged us
to express the full-length receptor in the same host. Despite its large size, we were successful at producing the full-length EGFR
protein fused to glutathione S-transferase (GST) that was detected by Western blot analysis. Moreover, we obtained a majoritarian
truncated GST-EGFR form detectable by gel electrophoresis and Western blot. This truncated protein was purified and confirmed
by MALDI-TOF/TOF analysis to belong to the N-terminal extracellular region of the EGFR fused to GST. Northern blot analysis
showed two transcripts suggesting the occurrence of a transcriptional arrest.
1. Introduction
Since its discovery, the epidermal growth factor receptor
(EGFR) continues to be the subject of myriad investigations
in cancer signalling. EGFR is a transmembrane protein
composed of an extracellular region containing the ligand-
binding site, a transmembrane 𝛼-helix, and an intracellular
region harboring the tyrosine kinase domain, that is, flanked
by a juxtamembrane domain (JM) and a C-terminal tail.
The majority of solid tumor types overexpress at least one
of the EGFR family members (HER1/EGFR, HER2/Neu,
HER3, and HER4) [1]. As a consequence, the EGFR fam-
ily has been targeted by many antibodies for therapeutic
purpose, as many of them were approved to treat different
cancer types (i.e., breast, colorectal, and non-small cells
lung carcinoma (NSCLC), among others) [2]. Moreover,
many tyrosine kinase inhibitors (TKI) competing with ATP
binding were used to antagonize these receptors, and some
of them were approved also for treating some cancer types,
such as NSCLC [3]. Progress has been done in understand-
ing the EGFR activation process especially with research
aided by the crystallization of distinct segments of the
receptor.
The ligand-induced dimerization of the EGFR was
revealed by independent crystal structure studies show-
ing that both juxtaposed monomers are maintaining a
“butterfly”-like dimeric structure via a protruding loop from
each domain II [4, 5].
Stamos et al. solved the EGFR tyrosine kinase crys-
tal structure, encouraging the exploration of the relation-
ship between the active ectodomain (ECD) conformational
change and the intracellular activation of the tyrosine kinase
(TK) domain [6]. Many studies have tried to understand
the dimerization of the intracellular region of the EGFR
leading to autophosphorylation showing the importance of
the calmodulin-binding site located at the juxtamembrane
(JM) segment in this process [7–9]. An allosteric mechanism
of EGFR TK activation was proposed based on the formation
of an asymmetric dimer of the EGFR kinase domain [10],
where the JM region was shown to be the activator of the
allosteric mechanism [11–13].
The ECD is subdivided into four domains; domains I and
III are indispensable for ligand binding and domains II and
IV play a crucial role in receptor dimerization and activation.
There are 12 potential N-linked glycosylation sites in
the receptor, two in each of domains I and II and four in
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each of domains III and IV [14]. It was shown that the
glycosylation process is related to ligand-binding acquisition
[15], and core glycosylation plays an important role in both
EGF binding and kinase activation [16]. Treatment with tuni-
camycin yielded a 130 kDa aglycosylated form of the EGFR
with altered ligand-binding capacity, poor kinase activation,
and aberrant subcellular localization of the receptor [17].
Interestingly, the combination of tunicamycin and erlotinib
causedmore inhibitory effect on EGFR phosphorylation than
that induced by erlotinib alone [18]. Tsuda et al. suggested
that the sugar chain linked to Asn-420 of the ECD plays a
crucial role in EGF binding and prevents the spontaneous
oligomerization of the EGFR [19], which otherwise may
lead to uncontrollable receptor activation. Moreover, it was
shown that core glycosylation is responsible for EGFRvIII
self-dimerization [20].
Heterologous expression of the intracellular EGFR
domain [21, 22] or the ECD of some EGFR family members
was also attained in Escherichia coli and thereafter purified
yielding an active recombinant tyrosine kinase [22] that
allowed the preparation of antibodies [23, 24].
In the present work, we have modified the E. coli
culture conditions in order to improve the quantity and
quality of recombinant full-length and a truncated segment
of the EGFR expressed as a fusion with the GST tag. The
recombinant proteins could be used for the production of
corresponding anti-EGFR antibodies.
2. Materials and Methods
2.1. Strains and Reagents. E. coli strain BL21 CodonPlus
(Stratagene) was used for GST-fusion protein expression and
JM109 competent bacteria (Promega) were used for plasmid
construction and maintenance. The vector pLXSN, contain-
ing the full-length human EGFR, was a gift from Professor
Axel Ullrich (Max Planck Institute, Martinsried, Germany).
E. coli expression vector pGEX-6P-1 was purchased from
Amersham Pharmacia Biotech. Anti-EGFR (sc-03) and anti-
GST (sc-459) antibodies were obtained from Santa-Cruz
Biotechnology. The horseradish peroxidase conjugated anti-
rabbit and anti-mouse IgG antibodies were purchased from
Promega.
2.2. Plasmid Construction. The DNA fragment coding for
the full-length EGFR was amplified by PCR using Pfu-
polymerase (Stratagene) and the pLXSN-EGFR plasmid as
template. The following oligonucleotides were used for PCR
amplification: 5󸀠-GA GTC GAC CGA TGC GAC CCT CCG
GGA C-3󸀠, as forward primer, with a SalI site, underlined,
and 5󸀠-GAGCG GCC GCCCTCCGTGGT TCATGCTCC
A-3󸀠, as a reverse primer, with a NotI site, underlined. The
obtained fragment was double digested by SalI-NotI and
inserted in pGEX-6P-1. We used S-300 columns (Amersham
Pharmacia Biotech) to purify PCR products and a Qiagen
kit (QIAquick PCR purification kit) to remove restriction
enzymes fromdigestedDNAbefore ligation using the “ready-
to-go” T4 DNA ligase (Amersham Pharmacia Biotech). The
resulting construct, named pGEX-EGFR, was analyzed by
restriction enzymes and DNA sequencing to ascertain its
correctness.
2.3. Recombinant Protein Expression Analysis and Dimer-
ization. E. coli BL21 strains were grown overnight in
Luria’s broth or M9 minimal medium containing ampicillin
(75 𝜇g/mL). IPTG induction, expression analysis, and GST
proteins immobilization on glutathione-Sepharose 4B beads
were performed as previously described [22].
The dimerisation assaywas performed on 20𝜇g of protein
extract incubatedwith 150𝜇MBS3 for 10min at 4∘Cor 0.25M
glutaraldehyde for 1min at room temperature. The reaction
was stopped, respectively, by the SDS-PAGE loading buffer
or 0.6M glycine.
The proteins were then analysed on SDS-PAGE followed
by a Western blot using anti-EGFR or anti-GST antibodies.
2.4. In-Gel Protein Digestion and Sample Preparation for
MALDI-TOF/TOF Analysis. The bands of interest from
Coomassie colloidal-stained 1D gel were excised manually,
deposited in 96-well plates, and processed automatically
in a Proteineer DP (BrukerDaltonics, Bremen, Germany).
The digestion protocol used was based on Shevchenko et
al. [25] with minor variations: gel plugs were washed first
with 50mM ammonium bicarbonate then with acetonitrile
(ACN) prior to reduction with 10mM dithiothreitol in
25mM ammonium bicarbonate solution. Alkylation was
carried out afterwards with 55mM 3-𝛽-indole acrylic acid
(IAA) in 50mM ammonium bicarbonate. Gel pieces were
rinsed with 50mM ammonium bicarbonate and thereafter
with ACN and were dried under a stream of nitrogen.
Modified porcine trypsin (sequencing grade; Promega,Madi-
son, WI) was added at a final concentration of 16 ng/𝜇L
in 25% ACN/50mM ammonium bicarbonate solution and
the digestion was incubated at 37∘C for 6 h. The reaction
was stopped by adding 0.5% trifluoroacetic acid (TFA). The
tryptic-eluted peptideswere dried by speed-vacuumcentrifu-
gation and were resuspended in 4 𝜇L of MALDI solution. A
0.8 𝜇L aliquot of each peptide mixture was deposited onto a
389-well OptiTOF Plate (Applied Biosystems, Framingham,
MA) and allowed to dry at room temperature. Matrix solu-
tion (3mg/mL 𝛼-cyano-4-hydroxycinnamic acid (CHCA) in
MALDI solution) was then added (0.8𝜇L) and the mixture
was dried at room temperature.
2.5. MALDI Peptide Mass Fingerprinting, MS/MS Analysis,
and Database Searching. For MALDI-TOF/TOF analysis,
samples were automatically acquired in an ABi 4800 MALDI
TOF/TOFmass spectrometer (Applied Biosystems, Framing-
ham,MA) in positive ion reflectormode (the ion acceleration
voltage was 25 kV for MS acquisition and 1 kV for MS/MS)
and the obtained spectra were stored into the ABi 4000
Series Explorer Spot Set Manager. Peptide mass finger-
printing (PMF) and mass spectrometry/mass spectrometry
(MS/MS) fragment ion spectra were smoothed and corrected
to zero baseline using routines embedded in ABi 4000 Series
Explorer Software v3.6. Each PMF spectrum was internally
calibrated with the mass signals of trypsin autolysis ions
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Figure 1: GST-EGFR expression in E. coli BL21 strain. The proteins
were separated in a 10% SDS-PAGE and stained with Coomassie
blue. (Lanes 1 and 2) Two clones of E. coli BL21 cells transformed by
empty pGEX-6P-1 vector. (Lanes 3–6)Different clones of E. coliBL21
cells transformed by pGEX-EGFR. (Lane M) The protein masses of
the BioRad markers are indicated in kDa. The arrows point to GST
and the ≈50 kDa protein.
to reach a typical mass measurement accuracy of <25 ppm.
Known trypsin and keratin mass signals, as well as potential
sodium and potassium adducts (+21Da and +39Da, resp.),
were removed from the peak list. To submit the combined
PMF and MS/MS data to MASCOT software v.2.1 (Matrix
Science, London,UK),GPSExplorer v4.9was used, searching
in the nonredundant NCBI protein database.
2.6. E. coli Total RNA Extraction and Northern Blot Anal-
ysis. After solubilization, cells were solubilized in Eurosol
(EuroClone) solution and chloroform was added in the
proportion of 1 : 10. After mixing and 5-minute incubation
on wet ice, the sample was centrifuged for 15min at 12,000 g.
The upper aqueous phase containing RNAwas then collected
and precipitated with cold isopropanol for 15min on wet ice.
After centrifugation at 12,000 g at 4∘C, the total RNA pellet
was washed with 75% ethanol and centrifuged at 8,000 g for
15min at 4∘C. Northern blot analysis was performed accord-
ing to Sambrook and Russel [26]. A PCR fragment corre-
sponding to the EGFR ECD was [32P]dCTP-radiolabelled by
Rediprime II Random Prime Labelling System (Amersham)
and used as a probe to detect EGFR messengers.
3. Results
3.1. Expression of Recombinant EGFR in FusionwithGST. The
DNA fragment encoding the open reading frame (ORF) of
the EGFRwas amplified using pLXSN-EGFR as template and
inserted in frame with the ORF of the GST in pGEX-6P-1.
The obtained construct, pGEX-EGFR, was used to transform
BL21 CodonPlus. In order to optimize the expression of
full-length GST-EGFR, we have varied the culture media
and analyzed the produced proteins in each condition by
Western blot. After culture/induction of the recombinant
strains as described in Section 2, cells were solubilized in
loading buffer and total proteinswere analyzed in SDS-PAGE.
The analysis displays amajor ≈50 kDa band corresponding to
a truncated form of the EGFR (Figure 1).The detection of this
truncated formwas confirmed byWestern blot analysis using
the anti-GST as primary antibody (Figure 2(a)). Moreover,
a longer exposition to ECL allowed the detection of a
160 kDa band corresponding to the full-length GST-EGFR
(Figure 2(b)). The full-length GST-EGFR was also detected
by the anti-EGFR antibody, especially after immobilization in
glutathione beads of the recombinant protein derived from E.
coli grown in M9 minimal medium (Figure 2(c)).
The dimerization of the receptor was also studied via
BS3 chemical cross-linking and glutaraldehyde. Our results
showed that the full-length GST-EGFR preserved the ability
of forming dimers even in the absence of EGF (data not
shown).
3.2. Analysis of the GST-EGFR Truncated Form. In order
to understand the origin of EGFR truncation and check
the integrity of its ORF, the ≈50 kDa truncated GST-
EGFR protein overproduced in all media used was puri-
fied from the SDS-PAGE as described in Section 2. After
trypsin digestion, this protein was subjected to MALDI-
TOF/TOF analysis (Figure 3). Many peaks from the obtained
spectrum were identified as peptides belonging to the
GST or the EGFR proteins using the Mascot search tool
(http://www.matrixscience.com/) (Figure 3). The identifica-
tion of the obtained peptides showed that the truncated pro-
tein starts from the GST and stops at domain II of the EGFR
according to the matched peptides (Figure 3(c)). According
to the last matched peptide, the truncation corresponds to
the first 293 amino acids of EGFR protein sequence which
becomes 530 residues with the GST.The size of this truncated
protein (≈50 kDa) was determined by the Expazy proteomic
tools (PeptideMass at http://www.expasy.org/tools/).The cor-
responding mRNA size was 1590 bp (879 bp corresponds to
the EGFR RNA).
Northern blot analysis using a PCR probe corresponding
to the EGFRECD showed the presence of two transcripts.The
small one is present even in noninduced cells but the large one
is produced after IPTG stimulation only (Figure 4).
These results suggest that the largest transcript encodes
the full-length GST-EGFR while the smaller one, expressed
even in the absence of IPTG induction, is probably encoding
the truncated protein. The presence of the small transcript
under noninduced condition could be explained by the
“leaky” expression encountered with the pGEX vectors as
described by the supplier.
4. Discussion
The production of EGFR protein in an easy and less costing
host could facilitate enormously the production of specific
antibodies or screening for tyrosine kinase antagonists. For
long time E. coli has been an ideal heterologous expression
host characterized by the multiplicity of developed strains
and the continuous production/purification improvement of
the recombinant proteins.Wehave previously succeededwith
the expression andproduction of an active intracellular EGFR
domain [22], which encouraged our present work. We now
achieved expressing the full-length EGFR as a GST-fusion
protein that was detectable only by Western blot analysis.
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Figure 2: Western blot analysis of GST-EGFR. Samples from E. coli expressing GST (lane 1) and GST-EGFR (lanes 2–4) were processed by
Western blot with the anti-GST antibody. (a) 5min ECL exposure; (b) 30min ECL exposure; (c) the protein extract was immobilized on
glutathione-Sepharose beads, run on SDS-PAGE, and analyzed by Western blot using the anti-EGFR antibody. (Lane P) Protein extract of E.
coli cells transformed with empty pGEX-6P-1. (Lane E) Protein extract of E. coli cells transformed with pGEX-EGFR after immobilization on
glutathione beads. Arrows indicate the position of each expressed recombinant protein.
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Figure 3: Identification of the truncated protein by MALDI-TOF/TOF analysis. (a) The gel in the inset shows the purified N-terminal
truncated EGFR with its corresponding size. The protein masses of the BioRad markers are indicated in kDa. (b) The spectrum shows
different peaks of theMS analysis done byMALDI-TOF.TheN-terminal truncated EGFR (≈50 kDa) was subjected to in-gel trypsin digestion
before MALDI-TOF analysis. The arrows show the peaks that served for MS/MS analysis with their corresponding masses used for protein
identification. (c) MASCOT results: matched peptides to EGFR sequence are shown in capital bold; the last identified peptide ends at K293.
Moreover chemical cross-linkingwith BS3 showed that EGFR
dimerization is preserved in E. coli.
The expression of EGFR was concomitant with the pro-
duction of the ≈50 kDa truncated protein that was analyzed
in MALDI-TOF/TOF, and the MASCOT search confirmed
its identity corresponding to a truncation within the ECD
domain II of the receptor. The origin of this truncation was
analyzed by Northern blot, and the presence of two tran-
scripts was detected: a larger one that was dependent on IPTG
stimulation of the promoter and is more probably encoding
the full-length GST-EGFR protein and a shorter transcript
that is present even in the absence of IPTG induction and
could encode the truncated protein. The presence of this
small transcript in noninduced cells is very likely due to
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Figure 4: Northern blot analysis of EGFR expression. (a) Total RNA
(20 𝜇g) was loaded on a formaldehyde 1.5% agarose gel. RNA was
extracted from E. coliBL21 cells transformedwith pGEX-EGFR after
one-hour induction with 0.1mM IPTG (lane 1) or without induction
(lane 2). Extracted RNA of E. coli BL21 cells transformed with empty
pGEX-6P-1 after one-hour induction with 0.1mM IPTG (lane 3) or
without IPTG induction (lane 4) used as control. (b)The gel inAwas
blotted on a nitrocellulose membrane and radioactive hybridization
was performed with a 1.9 kb PCR fragment of EGFR ECD cDNA.
a premature transcriptional termination signal within the
EGFR cDNA, although this arrest was not total since the
detection of the full-length transcript and protein was appar-
ent.This could be explained by the existence of a transcription
attenuation phenomenon due to E. coli-like leaky terminator
signals within the EGFR cDNA sequence. We have scanned
the EGFR cDNA sequence by several online programs and
found two overlapping hairpin structures resembling those of
the tryptophan operon. In fact, the sequence of EGFR cDNA
(starting from the ATG) 1220–ttcaggct-1227 hybridizes with
the sequence 1331-aagtccga-1324 in a first palindrome and
with the sequence 1236-aagtccg-1230 in another palindrome.
Favoring one of these two palindromes could be responsible
for the present transcription attenuation.
Furtherwork should be performed to establish themolec-
ular basis of this premature termination in transcription of
the full-length EGFR and on the possibility of bypassing
this arrest in order to express larger quantities of the full-
length receptor. Meanwhile, the overexpression of the 50 kDa
truncated protein could serve itself for the production of
anti-EGFR antibodies directed against the N-terminal of the
receptor.
5. Conclusions
The adoption of E. coli as a host of heterologous expression
is still a primordial strategy for any gene functional or
immunogenicity study. The present work demonstrates that
this strategy is valuable also for transmembrane proteins like
receptor tyrosine kinases, which could facilitate proteomic
studies. Moreover, encountering an E. coli-like transcription
arrest signal within a human oncogene could have many
impacts. Since EGFR has its viral homolog, ErbB, one can
speculate the occurrence of DNA transfer from prokaryotic
to eukaryotic genomes through viruses.We have to search for
analogous results of expression to check our hypothesis.
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